U.S. FDA recommends pause on Johnson & Johnson vaccine amid blood clot concerns
Johnson & Johnson's single-dose COVID-19 vaccine has hit a stumbling block in the United States as regulators begin investigating reports of blood clots, weeks before the first shipment of the jabs are expected to arrive in Canada.
The U.S. Centers for Disease Control and Prevention and the Food and Drug Administration said Tuesday they were investigating clots in six women that occurred in the days after vaccination. The agencies are recommending pausing the use of the Johnson & Johnson jab in the country.
It's the second COVID vaccine to be investigated for a possible link to blood clotting after several European countries temporarily halted use of the Oxford-AstraZeneca vaccine for the same reason last month.
Canada approved the Johnson & Johnson vaccine in early March, but manufacturing issues have delayed shipments.
Health Canada said Tuesday it is investigating the latest reports, and Prime Minister Justin Trudeau noted the country is still on track to receive its first shipment at the end of April.
The company said it's delaying rolling out its vaccine in Europe amid the U.S. investigation.
The Johnson & Johnson reports appear similar to the rare type of clotting disorder that European authorities said last week is possibly linked to AstraZeneca. The European Medicines Agency has said the benefits of receiving the AstraZeneca jab outweigh the potential risks.
More than 6.8 million doses of the shot have been administered in the U.S., with the vast majority reporting no or mild side effects.
Both Johnson & Johnson and AstraZeneca use the same vaccine technology, which differs from the mRNA vaccines from Pfizer-BioNTech and Moderna.
Here's how the four vaccines work:
All of the approved COVID-19 vaccines train the body to recognize the spike protein that coats the outer surface of the coronavirus.
Johnson & Johnson and AstraZeneca use a harmless version of a cold virus as a vector to give our cells the instructions they need to make the coronavirus's spike protein.
The immune system recognizes the protein and makes antibodies, which then allow us to fend off attack if exposed in the future.
Johnson & Johnson uses a human adenovirus, or a cold virus, to create its vaccine while AstraZeneca uses a chimpanzee version.
Johnson & Johnson's is the first single-dose vaccine approved in Canada. AstraZeneca, like Pfizer and Moderna, requires two doses.
Experts say it takes a couple weeks for the body to build up some level of immunity with any of the vaccines.
Messenger RNA Vaccines
Moderna and Pfizer use messenger RNA (mRNA), a novel technology that essentially teaches our cells how to produce the coronavirus's spike protein. That triggers an immune response if we become infected with the virus in the future.
All four of the vaccines basically work the same way, but there's one less component involved with the mRNA versions.
Whereas the viral vectors use another virus to give our cells the info they need to make the spike protein, mRNA dumps the genetic code in directly, without using another virus as a vessel.
Pfizer and Moderna use synthetically-produced mRNA that's packaged in a fat coating. The mRNA is dumped into the cell when the vaccine is injected into the arm muscle and it then translated into protein to make the antibody.
The vaccines from Pfizer and Moderna were the first inoculations approved for humans to use mRNA, but the technology was being worked on for decades before it was adapted to vaccine creation.
Previous research had been done on creating mRNA vaccines against Zika and other viruses, and there were earlier efforts focused on cancer treatments.
Early pitfalls against the mRNA technology was that it was too unstable and fragile, with the mRNA disintegrating upon entering the body. That problem was solved by packaging it in the fat coating, giving it something to help bind onto cells easier.
-- With files from The Associated Press
BNN Bloomberg Picks
How to apply for the new Canada Dental Benefit
Tips to deal with shrinkflation at the mall as some shoppers question discounts
TD says 'irregular activity' alert prompted pause of Canada Post loan program
4 reasons for thrift store gifts this year
What the new GDP report might mean for the next Bank of Canada decision
Real estate in 2023: Re/Max forecasts 3.3% decline in home prices